CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 87,292	$ 89,959
Short-term marketable securities	45,558	83,506
Receivables from collaborative arrangements	12,488	14,065
Amounts due from TRC, LLC		43,534
Prepaid clinical and development services	2,311	10,245
Other prepaid and current assets	7,080	8,561
Total current assets	154,729	249,870
Property and equipment, net	12,531	13,657
Operating lease assets	41,112	39,690
Equity in net assets of TRC, LLC	148,250	67,537
Restricted cash	836	837
Other assets	3,303	3,228
Total assets	360,761	374,819
Current liabilities:
Accounts payable	3,074	3,098
Accrued personnel-related expenses	6,958	12,796
Accrued clinical and development expenses	7,627	17,010
Accrued general and administrative expenses	6,052	2,898
Accrued interest payable	3,990	3,940
Current portion of non-recourse notes due 2035, net		16,940
Operating lease liabilities	2,624	503
Deferred revenue	24	98
Other accrued liabilities	2,275	1,304
Total current liabilities	32,624	58,587
Convertible senior notes due 2023, net	228,571	228,035
Non-recourse notes due 2035, net	396,125	371,359
Long-term operating lease liabilities	50,642	52,681
Long-term deferred revenue	204	310
Other long-term liabilities	2,404	2,420
Commitments and contingencies
Shareholders' Deficit
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 76,427 and 74,435 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	1	1
Additional paid-in capital	1,410,415	1,387,469
Accumulated other comprehensive loss	(45)
Accumulated deficit	(1,760,180)	(1,726,043)
Total shareholders' deficit	(349,809)	(338,573)
Total liabilities and shareholders' deficit	$ 360,761	$ 374,819